Skip to Main Content
Contribute Try STAT+ Today

Even in the bleak world of cancer, there are terrible and less terrible diagnoses, with nothing grimmer than finding that a just-discovered tumor has already spread to vital organs like the lungs, liver, bones, or brain. It’s not just the extent of the cancer. Worse, such metastases were long thought to be genetic Towers of Babel, each speaking such a different genetic language that no one DNA-targeted drug could treat all of them.

That assumption, it turns out, is probably wrong: Scientists reported on Thursday that, in any one patient, untreated metastases are driven by the same genetic mutations, whether they’re in the lung or liver or anywhere else. That conclusion, based on the most extensive analysis to date of metastatic tumors, bodes well for targeted therapies, because it means a single drug should work against all of a patient’s metastases — and it is the metastases, not the primary tumor, that are responsible for 90 percent of cancer deaths.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Great information platform!
    Thank you to all those working behind the scenes for better health in the world!

  • A ‘single magic bullet’ always sounds too good to be true.
    Metastases, while sharing some key mutations, probably have
    others that may be unique or may only be shared by a subset.
    Such is life….

Comments are closed.